Phase I
The company said it would halt activities and focus its resources and time on liver and obesity research following “disappointing” results of its intranasal COVID-19 vaccine.
Interim results from the Phase I study presented at the Peripheral Nerve Society Annual Meeting demonstrated that the investigational therapy, NTLA-2001, greatly reduced the disease-causing protein after a single infusion.
In what will be a big moment for CRISPR technology, Intellia and development partner, Regeneron Pharmaceuticals will share the world’s first data from a therapy that edits flawed genes inside the body.
The U.S. Food and Drug Administration (FDA) has made the decision to grant Breakthrough Therapy Designation to Mirati Therapeutics’ adagrasib for the potential treatment of non-small cell lung cancer (NSCLC) in patients harboring the KRASG12C mutation after systemic therapy.
It was a busy week for clinical trial news. Here’s a look.
The decision to exercise the option was based on an interim analysis of the ongoing Phase I trial of TNB-383B.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The two companies will assess the safety and immunogenicity of the vaccine candidate, which codes for the hemagglutinin protein in the A/H3N2 strain of the seasonal flu virus.
It was another busy week of clinical trial announcements. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their business operations and pipelines.
PRESS RELEASES